CSPC Pharma wins China approval: meaning for CSPC Pharma stock
Published on 10/25/2026 at 00:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline and financial markers
- CSPC received one batoclimab registration certificate on October 23, 2026.
- First-half 2026 revenue reached RMB 18,594 million, up 40.1 percent.
- CSPC Pharma stock was last at HKD 8.35 on October 23, 2026.
- The company set a November 10, 2026 payment date for its HKD 0.18 dividend.
CSPC Pharma (ISIN HK1093012172) said on October 23, 2026, that batoclimab injection had received one drug registration certificate from China's National Medical Products Administration, according to the company's CSPC Pharma. The approval adds a commercial-stage regulatory milestone to a pipeline that is also producing new clinical data.
The company's 2026 interim results provide the financial counterweight. Revenue for the first half of 2026 reached RMB 18,594 million, up 40.1 percent from the first half of 2025, while reported profit attributable to shareholders rose 139.2 percent to RMB 6,094 million, according to CSPC Pharma.
Three pipeline steps since October 8
On October 8, 2026, CSPC presented phase I SYS6002 data involving 82 patients, with confirmed objective response rates of 35.9 percent and 28.6 percent in two dosing cohorts, as reported by Simply Wall St.
On October 20, 2026, the company began a phase I trial of SYH2083 eye drops for dry eye disease in China. On October 23, 2026, the batoclimab approval followed, creating three dated pipeline events within 15 days, with the latest event carrying the clearest regulatory consequence, according to MarketScreener and the company update.
What does the approval mean for earnings?
The immediate answer is timing rather than a new earnings forecast. The 2026 interim report already showed underlying profit of RMB 6,164 million, up 165.8 percent year over year, while basic earnings per share rose 139.8 percent to RMB 0.5345 for the first half, according to CSPC Pharma. Batoclimab therefore adds a regulatory milestone to a period that already contains quantified earnings growth.
Dates investors can verify
The next substantiated corporate date is November 10, 2026, when the company is scheduled to pay an HKD 0.18 dividend. A market calendar lists November 19, 2026, as the next earnings date for CSPC Pharmaceutical Group, according to Yahoo Finance.
Hong Kong quote follows pipeline news
CSPC Pharmaceutical Group was last at HKD 8.35 on the Hong Kong Stock Exchange on October 23, 2026 at 4:08 p.m. HKT. Its 52-week range was HKD 6.53 to HKD 10.96, while market capitalization stood at HKD 95.2 billion on the same date.
The further course of trading is shown by the continuously updated real-time quote of CSPC Pharma stock.
CSPC Pharma key data
- Company: CSPC Pharmaceutical Group Limited
- ISIN: HK1093012172
- Ticker: 1093.HK
- Primary exchange: Hong Kong Stock Exchange
- Market capitalization: HKD 95.2 billion (as of October 23, 2026)
- 52-week range: HKD 6.53-10.96 (as of October 23, 2026)
- Sector / Industry: Pharmaceuticals
Market context: Latest market reports.
